4 Analysts Have This to Say About Pacira BioSciences
Portfolio Pulse from Benzinga Insights
Pacira BioSciences (NASDAQ:PCRX) has received 3 bullish and 1 somewhat bullish ratings from analysts in the last quarter. The average 12-month price target for the company is $58.25, representing a 12.18% decrease from the previous average price target of $66.33.
August 04, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pacira BioSciences has received positive ratings from analysts, but the average price target has decreased, indicating a potential decrease in stock price.
Analyst ratings are a significant factor in stock performance. While Pacira BioSciences has received mostly positive ratings, the decrease in the average price target could indicate a potential decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100